Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Edward Bausch transformed the world of optics with groundbreaking inventions like the iris diaphragm shutter and advanced ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...